Avidity Biosciences, Inc.
Clinical trials sponsored by Avidity Biosciences, Inc., explained in plain language.
-
New drug aims to ease muscle stiffness in rare disease
Disease control OngoingThis phase 3 study tests an experimental drug called AOC 1001 for myotonic dystrophy type 1, a genetic condition that causes muscle weakness and stiffness. About 159 adults who can walk independently are receiving either the drug or a placebo to see if it improves hand function, …
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 26, 2026 12:06 UTC
-
New hope for DM1: Long-Term trial of AOC 1001 begins
Disease control ENROLLING_BY_INVITATIONThis study is for people with myotonic dystrophy type 1 (DM1) who have already taken part in earlier AOC 1001 trials. It aims to see if the drug is safe and works well over a longer period. About 230 adults will receive the medicine by IV and be monitored for side effects and ben…
Phase: PHASE3 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New hope for FSHD: Long-Term drug safety trial underway
Disease control OngoingThis study looks at the long-term safety and effectiveness of a drug called AOC 1020 for people with FSHD, a genetic disease that causes muscle weakness. About 84 adults who completed a previous study will receive the drug through an IV. The main goal is to check for side effects…
Phase: PHASE2 • Sponsor: Avidity Biosciences, Inc. • Aim: Disease control
Last updated May 18, 2026 12:08 UTC